Reply to "Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer." by F. Graziano et al

from Cancer via ola Kala on Inoreader http://ift.tt/1QBIQQm
via IFTTT